Overview

  • Product name
    Fluvastatin sodium salt
  • Description
    Competitive HMG-CoA reductase inhibitor
  • Biological description
    Competitive HMG-CoA reductase inhibitor (IC50 = 40 - 100 nM in human and rat microsomes). Potent inhibitor of vascular smooth muscle cell proliferation in vitro (IC50 = 70 nM).
  • Purity
    > 99%

Properties

Applications

Our Abpromise guarantee covers the use of ab120651 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Functional Studies Use at an assay dependent concentration.

Images

  • ab90529 staining cytochrome C in HepG2 cells treated with fluvastatin sodium salt (ab120651), by ICC/IF. Increase of cytochrome C expression correlates with increased concentration of fluvastatin sodium salt, as described in literature.
    The cells were incubated at 37°C for 48 hours in media containing different concentrations of ab120651 (fluvastatin sodium salt) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab90529 (1 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.

References

This product has been referenced in:
  • Yang J  et al. The cardioprotective effect of fluvastatin on ischemic injury via down-regulation of toll-like receptor 4. Mol Biol Rep 38:3037-44 (2011). Read more (PubMed: 20127518) »
  • Turner NA  et al. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J Cardiovasc Pharmacol 50:458-61 (2007). Read more (PubMed: 18049315) »
  • Morikawa-Futamatsu K  et al. HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1. Life Sci 79:1380-90 (2006). Read more (PubMed: 16712874) »

See 0 Publications for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab120651.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"

Sign up